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Parkinson’s disease (PD) has a number of known genetic risk factors. Clinical and epidemiological studies have
suggested the existence of intermediate factors that may be associated with additional risk of PD. We construct
genetic risk profiles for additional epidemiological and clinical factors using known genome-wide association
studies (GWAS) loci related to these specific phenotypes to estimate genetic comorbidity in a systematic
review. We identify genetic risk profiles based on GWAS variants associated with schizophrenia and Crohn’s
disease as significantly associated with risk of PD. Conditional analyses adjusting for SNPs near loci associated
with PD and schizophrenia or PD and Crohn’s disease suggest that spatially overlapping loci associated with
schizophrenia and PD account for most of the shared comorbidity, while variation outside of known proximal
loci shared by PD and Crohn’s disease accounts for their shared genetic comorbidity. We examine brain methy-
lation and expression signatures proximal to schizophrenia and Crohn’s disease loci to infer functional changes
in the brain associated with the variants contributing to genetic comorbidity. We compare our results with a sys-
tematic review of epidemiological literature, while the findings are dissimilar to a degree; marginal genetic asso-
ciations corroborate the directionality of associations across genetic and epidemiological data. We show a
strong genetically defined level of comorbidity between PD and Crohn’s disease as well as between PD and
schizophrenia, with likely functional consequences of associated variants occurring in brain.
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INTRODUCTION
Parkinson’s disease (PD) is recognized to be associated with a
number of genetic susceptibility factors, including variability at
the loci SNCA, LRRK2, MAPT, BST1, GAK, HLA-DR, ACMSD,
STK39, MCCC1/LAMP3, SYT11, CCDC62/HIP1R, PARK16/
1q32, STX1B/16p11, FGF20/8p22, STBD1/4q21, GPNMB/7p15,
among others, which have been identified in genome-wide asso-
ciation studies (GWAS). It is likely that other additional genetic
risk factors also contribute. PD has been reported to be associated
with a number of clinical comorbidities and altered laboratory
values, such as affective disorders and serum urate levels. Sev-
eral of these have themselves been associated with genetic sus-
ceptibility factors, for which information is available from the
NHGRI GWAS catalog (http://www.genome.gov/26525384, (1)).
This offers the opportunity to examine genetic risk profiles
associated with these clinical phenotypes as risk factors for
PD. Genetic risk profiles may be thought of as the cumulative
genetic load of risk alleles related to a particular disease or
trait, explaining more of the attributable genetic risk associated
with this disorder than a single SNP itself. While many epi-
demiological studies examine associations between intermedi-
ate phenotypes and a specific outcome, in this study we sought
to examine how the genetic risk profiles associated with these
intermediate phenotypes may be associated with PD risk them-
selves. We sought to identify genetic comorbidities of PD by
testing associations with genetic risk profiles previously asso-
ciated with intermediate phenotypes of interest. Any disease or
trait with a significant risk profile score associated with PD es-
sentially would share some genetic factors in common.
In this study, we identify PD genetic comorbidities such as
Crohn’s disease and schizophrenia. We also attempt to dissect
the individual contributions of these associated loci in their con-
tributions to PD risk. Additionally, we utilize expression and
methylation data to infer functional genetic consequences in
brain tissues associated with these genetic comorbidities.
RESULTS
We used a large sample series of.5000 PD cases and 9000 con-
trols with genome-wide genotyping data (Table 1). We defined a
list of clinical factors that are potentially associated with PD risk
or comorbidity. We then examined how SNPs associated with
these clinical factors might be associated with PD itself using a
measure of the cumulative effect of all SNPs related to that par-
ticular factor (Supplementary Material, Tables S1 and S2). We
identified 18 clinical factors suggested by the literature and clin-
ical observation to be possible factors associated with PD for
which there were high-quality GWAS results in the NHGRI cat-
alog (http://www.genome.gov/26525384, (1)). These include:
serum amyloid, bipolar disorder, caffeine intake, Crohn’s dis-
ease, hypertension, inflammation, serum iron, melanoma, obe-
sity,PD,psoriasis, rheumatoidarthritis, schizophrenia, smoking,
type 2 diabetes, ulcerative colitis and serum urate (2–68). As a
note, PD was included as a positive control. For these phenotypes
of interest, alleles associated with an increase in risk for binary
phenotypes and/or alleles associated with increase in the level
of continuous phenotypes were summed to create the genetic
risk profiles.
Within each of the five IPDGC cohorts participating in this
analysis, each risk profile comprising a number of SNPs was
tested using logistic regression for an association with PD
status, adjusting for sex, age at onset/exam and population sub-
structure. Summary statistics from each cohort were combined
through meta-analysis under random effects to account for pos-
sible heterogeneity (see Figure 1 and Table 2). This resulted in
three genetic risk profiles being significantly associated with
PD. These include profiles based on SNPs taken from studies
of Crohn’s disease, schizophrenia and PD. A single standard de-
viation increase in the genetic risk profile for PD, equivalent to
roughly a 34% increase in the genetic burden associated with
known PD risk alleles within a population, was associated with
an odds ratio (OR) of 1.29 (95% confidence interval 1.22–1.38,
P-value,2E216). Using the same burden scale, a single stand-
ard deviation increase from population means in the allelic
burdens derived from Crohn’s disease and schizophrenia risk
profiles was significantly associated with PD status at an OR of
1.06 (95% confidence interval 1.02–1.11, P-value 0.005) and
1.05 (95% confidence interval 1.01–1.10, P-value 0.012),
respectively.
All 96 SNPs within these three risk profiles (Crohn’s disease,
PD and schizophrenia) were tested independently for association
with PD using identical statistical models and meta-analytic
methods as described for the analyses of risk profiles (Supple-
mentary Material, Table S3). Two SNPs not previously known
to be associated with PD passed Bonferroni correction for 99
tests. The first was rs11191580, a SNP in the NT5C2 gene
known to be associated with schizophrenia. This SNP reached
genome-wide significance in our testing (risk associated with
reference allele T at OR 1.35, 95% confidence interval 1.21–
1.50, P-value 3.98E28, T frequency 91.2%). The region sur-
rounding rs11191580 was suggested to be associated with PD
Table 1. Descriptive statistics of cohorts contributing to analyses
Cases Controls
Cohort Age at onset,
mean (SD) in years
% Female n Age at enrollment,
mean (SD) in years
% Female n
France 57.548 (13.086) 41.523 985 73.736 (5.373) 42.843 1984
Germany 55.715 (11.549) 39.595 740 47.416 (12.376) 47.987 944
Netherlands 55.649 (11.826) 36.446 771 55.721 (5.771) 56.028 2024
NIA—USA 57.812 (13.156) 40.235 937 61.933 (11.599) 24.525 1896
UK 64.167 (12.434) 42.051 1648 53 (0) 48.388 2699
NIA denotes cohorts with data generated at the Laboratory of Neurogenetics at the National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
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initially in a previous publication by Simon-Sanchez et al. using
a portion of the IPDGC data (42). However, the association at
this locus was never definitively replicated in a European ances-
try population and was therefore not included in the PD genetic
risk profiles we have constructed in this report (42). The other
SNP passing Bonferroni correction was rs11564258, a SNP
near the LRRK2 risk locus from the Crohn’s disease risk
profile, at an OR of 0.69 associated with the G reference allele
(95% confidence interval 0.58–0.83, P-value 5.49E25, G fre-
quency 97.5%) showing possible LD with the LRRK2 PD risk
locus (49).
To assess the independence of the risk profile associations
outside of possible spatial overlaps with PD loci, risk profile
score associations were recalculated adjusting for SNPs near PD
risk loci as covariates. Keller et al.’s summary of PD loci was
used, in addition to data mined from the GWAS catalog to
further scrutinize putative PD loci (69). To define SNPs used as
covariates, they must be within 1 mb of a PD risk locus described
in either the downloaded GWAS catalog, Keller et al. or Simon-
Sanchez et al. (1,42,69). When adjusting for SNPs near PD risk
loci as covariates, the schizophrenia risk profile association was
reevaluated adjusting for rs11191580 and rs7914558 in NT5C2
and rs3131296 near the HLA-DRA risk locus as additional covari-
ates. The Crohn’s disease risk profile association was adjusted for
rs11564258 and rs11175593 near LRRK2, rs17309827 near
HLA-DRA and rs1736135 near the suspected PD risk locus at
USP25. After meta-analyzing the cohort-specific summary statis-
tics adjusted for these SNPs, the association between the Crohn’s
disease’s risk profile remained significantly associated with PD
risk (OR 1.05, 95% confidence interval 1.01–1.09, P-value
0.03), while the schizophrenia association was completely attenu-
ated (OR 0.99, 95% confidence interval 0.92–1.06,P-value 0.76).
This suggests that there are additional genetic factors outside of
known PD loci overlap that contribute to the genetic comorbidity
shared by PD and Crohn’s disease, while the genetic comorbidity
shared by schizophrenia and PD may simply be due to possible
overlapping loci, although the association at NT5C2 in PD
remains to be definitively replicated.
Systematic review data were extracted for overlapping pheno-
types from Noyce et al. (1) to evaluate how genetic risk may be
Figure 1. Forest plots from random effects meta-analyses of profiled phenotypes. Cohort-specific OR associated with PD are shown in blue, the size of the square is
proportional to the size of the study. Confidence intervals of the summary OR per phenotype are shown as red diamonds, with the centerline of each diamond represent-
ing the summary OR for that particular phenotype. The dependent variable in each model is the standardized count of disease risk or quantitative measure increasing
alleles per sample associated with either disease status or continuous measures of interest. Abbreviations include Bipolar for bipolar disorder, IBD for inflammatory
bowel disease, T2DM for type 2 diabetes, Crohn’s for Crohn’s disease, UC for ulcerative colitis, Parkinson’s for Parkinson’s disease, Rheumatoid for Rheumatoid
arthritis, Smoking for smoking history/rate, Caffeine for caffeine or coffee consumption levels, amyloid for serum amyloid levels, iron for serum iron levels and urate
for serum urate levels.
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reflected in epidemiological data (Table 3). Neither Crohn’s
disease or schizophrenia associations were significantly repli-
cated in the epidemiological data, although the directionality
of effect for psychosis aspects of schizophrenia and Crohn’s
disease mirror genetic risk estimates associated with PD. The
directionality of effect in our study of genetic factors relating
to PD comorbidity leads support to the effects described in the
statistically significant epidemiologically evaluated comorbid-
ities of smoking status, coffee drinking and hypertension as
described in the systematic review.
Mining of brain tissue to infer possible biological functional-
ity at loci associated with PD, Crohn’s disease and schizophre-
nia, we examined regional methylation and expression data
within+1 mb of SNPs of interest in a large series of neurologic-
ally normal frontal cortex and cerebellar tissues. While we iden-
tified a number of loci significantly associated with methylation
and expression changes in the brain tissue samples, our primary
interest was to focus on SNPs from overlapping regions identi-
fied as risk loci for PD and Crohn’s or PD and schizophrenia
(Table 4). SNPs in the HLA region used to construct the Parkin-
son’s and schizophrenia profiles were significantly associated
with changes in regional methylation status in both the frontal
and cerebellar tissue samples, allowing us to infer functional
consequence in brain tissues associated with these proximal
risk SNPs. Alleles at this locus associated with risk of PD and
schizophrenia were concurrently associated with decreased
methylation in the frontal cortex (49). We also show that a
Crohn’s disease-associated SNP near the LRRK2 PD risk
locus is also significantly associated with methylation changes
in the frontal cortex. This suggests that genetic variants asso-
ciated with Crohn’s disease and schizophrenia (in addition to
PD) may alter brain function to some degree.
DISCUSSION
In this study, we identified Crohn’s disease and schizophrenia as
genetic comorbidities of PD. The genetic risk profiles based on
GWAS identified loci for these two diseases showed significant
risk associated with PD. The genetic comborbidity associated
with schizophrenia was almost entirely accounted for by SNPs
in the PD associated loci near NT5C2 and HLA-DRA. On the
other hand, Crohn’s disease’s risk profile and PD remained sig-
nificantly associated even when adjusting for overlapping SNPs
at loci near known PD risk loci USP25, HLA-DRA and LRRK2.
This suggests that additional risk loci associated with Crohn’s
disease are also connected to PD risk, outside of those already
near known PD loci. In the near future, deep sequencing of large
population based studies should help clarify further genetic co-
morbidities and provide greater insight into the mechanisms of
multiple related diseases.
There seems to be functional connectivity between these dis-
eases based on our analyses of expression and methylation data.
SNPs associated with both schizophrenia and Crohn’s disease
cause significant changes in proximal methylation and expres-
sion levels in the brain, allowing for the inference of functional
changes occurring in the brain related to these genetic comorbid-
ities. The associated changes in methylation and expression
status surrounding these SNPs mirrors their genomic context
in previous analyses related to PD (49,70). Future studies with
single cell capture designs, deep sequencing and additional
brain tissue regions sampled may better quantify possible func-
tional genetic consequences in PD etiology.
We recognize that a lack of clinical data on many of the parti-
cipants in the study pose problems. In particular, we are con-
cerned about the issue of drug-induced parkinsonism in this
Table 2. Summary statistics from random effects meta-analysis of profile phenotypes
Profiled phenotype OR Lower limit
of the OR 95%
confidence interval
Upper limit
of the OR 95%
confidence interval
Beta SE P-value I2 Heterogeneity
P-value
Amyloid 0.966 0.927 1.007 20.034 0.021 0.106 0 0.970
Bipolar 1.002 0.953 1.053 0.002 0.025 0.949 0.270 0.241
Caffiene 0.989 0.949 1.031 20.011 0.021 0.613 0 0.406
Crohns 1.061 1.018 1.106 0.059 0.021 0.005 0 0.688
Hypertension 0.988 0.948 1.030 20.012 0.021 0.569 0 0.867
IBD 1.038 0.987 1.092 0.038 0.026 0.143 0.284 0.232
Inflammation 1.032 0.991 1.076 0.032 0.021 0.131 0 0.535
Iron 0.982 0.942 1.024 20.018 0.021 0.388 0 0.986
Melanoma 1.005 0.965 1.048 0.005 0.021 0.796 0 0.583
Obesity 0.980 0.927 1.036 20.020 0.028 0.471 0.416 0.144
Parkinson 1.298 1.222 1.380 0.261 0.031 ,2E216 0.466 0.112
Psoriasis 0.962 0.912 1.015 20.039 0.027 0.155 0.359 0.182
Rheumatoid 0.975 0.934 1.019 20.025 0.022 0.259 0.065 0.370
Schizophrenia 1.055 1.012 1.100 0.053 0.021 0.012 0 0.424
Smoking 0.997 0.949 1.047 20.003 0.025 0.906 0.259 0.249
T2DM 0.993 0.953 1.036 20.007 0.021 0.756 0 0.734
UC 1.030 0.988 1.073 0.029 0.021 0.168 0 0.595
Urate 0.989 0.918 1.066 20.011 0.038 0.772 0.665 0.018
The dependent variable in each model is the standardized count of disease risk or quantitative measure increasing alleles per sample associated with either disease
status or continuous measures of interest. OR and beta coefficients correspond to a single standard deviation of change in the genetic profile for each phenotype based
on allele counts associated with an increase in disease risk or the level of quantitative phenotype. Abbreviations include IBD for inflammatory bowel disease, T2DM
for type 2 diabetes, UC for ulcerative colitis, SE denotes standard error of the beta coefficient from logistic regression and I2 is the index of heterogeneity.
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study and in other GWAS of both schizophrenia and PD. There is
a long history of drug-induced parkinsonism that is often acute in
onset (76), and misdiagnosis could affect the power and validity
of our current study. However, as part of the Queen Square Brain
Bank diagnostic criteria utilized to diagnose a majority of sam-
ples contributed to the IPDGC consortium effort, we believe
that the possible effect of drug-induced PD is minimal, as a con-
current diagnosis of schizophrenia was an exclusionary criteria
at study inception.
We recognize that there aresomeshortcomings in this analysis,
first and foremost is the lack of available data relating to inter-
mediate phenotypes in our PD consortium. The IPDGC datasets
contain little to no information regarding the 18 intermediate
exposures that would be necessary to conduct a true Mendelian
randomization (7, 77–80). A previous study of PD risk focused
on serum iron levels as the intermediate exposure has attempted
to extrapolate risk estimates from non-overlapping populations
and conduct an indirect Mendelian randomization based on
summary statistics from disparate cohorts in a complex and well-
conducted study, although this was logistically prohibitive in this
survey of multiple outcomes due to data availability and stand-
ardization issues across intermediate exposures (81). Due to lo-
gistic constraints, we opted to use this risk profiling method
instead, which could be applied within our consortium. While
this approach does not infer causality, it does elucidate comorbid
factors, and the associations between intermediate factors are dir-
ectly comparable using this method. In addition, this approach
can successfully identify comorbid intermediate factors asso-
ciated with PD, as this study has.95% power to detect an effect
at the magnitude of the schizophrenia and Crohn’s disease
Table 3. Systematic review of epidemiological literature for select traits of interest
Factor Study/studies (n) Cases
(n)
Controls
(n)
OR Lower limit
of the OR 95%
confidence
interval
Upper limit
of the OR 95%
confidence
interval
SE P-value I2 Heterogeneity
P-value
Ever versus never
smokinga
67 19 518 1 053 664 0.64 0.6 0.69 0.0347 ,0.001 49.60% ,0.001
Drinking versus
non-drinking
coffeea
19 5801 723 072 0.67 0.58 0.76 0.0684 ,0.001 42.90% 0.025
Hypertension
preceding PDa
12 5993 187 226 0.74 0.61 0.9 0.0989 0.003 76.50% ,0.001
Diabetes preceding
PDa
13 20 025 303 543 0.91 0.72 1.15 0.1189 0.423 70.90% ,0.001
Melanoma preceding
PDb
6 – – 1.07 0.62 1.84 – – 49.30% 0.079
Serum ironc 10 520 711 NS NS NS – – 93.40% ,0.0000
Bipolar disorder
preceding PD
Shiba et al. (71, 83) 196 196 1 0.1 16 – – NA NA
Psoriasis preceding
PD
Rugbjerg et al. (72, 84) 13 695 68 445 1.25 0.51 3.06 – – NA NA
Ulcerative colitis
preceding PD
Rugbjerg et al. (72, 84) 13 695 68 445 1.3 0.9 1.8 – – NA NA
Crohn’s disease
preceding PD
Rugbjerg et al. (72, 84) 13 695 68 445 1.06 0.54 2.1 – – NA NA
Rheumatoid arthritis
preceding PD
Rugbjerg et al. (72, 84) 13 695 68 445 0.7 0.5 0.9 – – NA NA
Blood inflammatory
markers preceding
PDd
Chen et al. (73, 85) 84 165 3.4 1.1 10.5 – – NA NA
Obesity preceding PDa 3/7 studies described significant associations with obesity preceding PD through a variety of different measures (RR/OR 2.8f, 2.03f, 0.43f,
0.9, 0.8, 0.86, 0.99)
Urate level preceding
PDa
3/5 studies described significant associations with elevated urate preceding PD using various cut-offs (ORs 0.4f, 0.6f, 0.71f, 0.43, 1.33) and 1
with preceding gout (OR 0.69f)
Schizophrenia
preceding PD$e
Two studies (Shiba et al. (71, 83): schizophrenia OR 1.0 (CI 0.1–7.0); Rajput et al. (74, 86): psychosis RR 1.5 (CI 0.3–6.7))
Serum amyloid No known epidemiological studies comparing serum amyloid levels between PD and controls
NS, non-significant but figures not provided; NA, not available; RR, relative risk.
aSummary data from meta-analysis undertaken by Noyce et al. (1).
bSummary data from meta-analysis undertaken by Liu et al. (86). NB: After exclusion of the only negative study OR 1.44 (CI 1.06–1.96); association of existing PD
with melanoma OR 3.61 (CI 1.49–8.77).
cSummary data from meta-analysis undertaken by Mariani et al. (87); data are for patients with established PD; Mariani et al. also report reduced transferrin and
transferrin saturation.
dOR refers to highest quintile of IL-6 compared with the lowest (P for trend 0.03). Associations with high-sensitivity c-reactive protein (CRP), fibrinogen and tumor
necrosis factor were non-significant. NB: In established PD, Song et al. (75, 87) reported increased high-sensitivity CRP compared with controls OR 2.04 (CI 1.18–
3.52).
eRisk of bias through drug-induced parkinsonism due to neuroleptic treatment.
fStatistically significant result (where confidence interval not given).
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Table 4. Local changes in mRNA expression and CpG methylation are associated with SNPs of interest for Crohn’s disease, PD and schizophrenia
SNP name Chromosome SNP
position (bp,
build 37)
Major allele,
minor allele
MAF Imputation
quality (RSQ
from
MiniMach)
Effect,
based on
minor
allele
dosage
Standard
error
P-value CpG or
mRNA
probe
Assay Tissue
sampled
Distance
from SNP to
probe (bp)
Probe-
associated
gene
Phenotype
rs2274910 1 160852046 C,T 0.2776 1 20.744 0.09 1.05E216 cg10106388 CpG methylation CRBLM 19384 CD244 Crohns
rs10181042 2 61224259 C,T 0.4224 0.9946 0.414 0.074 1.82E208 ILMN_1754501 mRNA expression FCTX 166006 NA Crohns
rs9858542 3 49701983 G,A 0.3273 0.8245 20.485 0.095 3.05E207 cg12788313 CpG methylation FCTX 24144 MST1 Crohns
rs9858542 3 49701983 G,A 0.322 0.6 20.553 0.099 2.06E208 ILMN_1690454 mRNA expression CRBLM 140324 FAM212A Crohns
rs2188962 5 131770805 C,T 0.4244 1 0.388 0.087 8.62E206 cg20512303 CpG methylation CRBLM 177896 PDLIM4 Crohns
rs2188962 5 131770805 C,T 0.4244 1 20.388 0.087 8.67E206 cg22598563 CpG methylation CRBLM 206884 P4HA2 Crohns
rs359457 5 173279842 T,C 0.4171 0.999 0.463 0.074 4.26E210 ILMN_1722025 mRNA expression CRBLM 105114 CPEB4 Crohns
rs359457 5 173279842 T,C 0.4171 0.999 0.672 0.075 2.31E219 ILMN_1722025 mRNA expression FCTX 105114 CPEB4 Crohns
rs13194053 6 27143883 T,C 0.1683 0.9872 0.516 0.109 2.26E206 cg14345882 CpG methylation FCTX 779090 BTN3A2 Schizophrenia
rs2021722 6 30174131 C,T 0.2031 0.9775 0.429 0.107 5.96E205 cg17475918 CpG methylation CRBLM 283056 HLA-E Schizophrenia
rs3131296 6 32172993 C,T 0.1409 0.9875 20.597 0.126 2.13E206 cg25764570 CpG methylation FCTX 234246 HLA-DRA Schizophrenia
rs2395163 6 32387809 T,C 0.2251 1 0.42 0.102 3.46E205 cg07363637 CpG methylation FCTX 540863 SLC44A4 Parkinson
rs2395163 6 32387809 T,C 0.2251 1 0.428 0.102 2.46E205 cg21415604 CpG methylation FCTX 439376 C4B Parkinson
rs3129882 6 32409530 A,G 0.4151 1 0.473 0.089 1.00E207 cg25764570 CpG methylation FCTX 2291 HLA-DRA Parkinson
rs2301436 6 167437988 C,T 0.4308 0.8426 20.35 0.081 1.50E205 ILMN_1671565 mRNA expression CRBLM 94917 RNASET2 Crohns
rs4077515 9 139266496 C,T 0.4247 0.9333 20.901 0.076 1.67E232 ILMN_1811301 mRNA expression CRBLM 56817 INPP5E Crohns
rs4077515 9 139266496 C,T 0.4247 0.9333 20.904 0.076 6.37E233 ILMN_1811301 mRNA expression FCTX 56817 INPP5E Crohns
rs7914558 10 104775908 G,A 0.3991 0.9932 20.696 0.086 5.20E216 cg00035347 CpG methylation FCTX 177700 NT5C2 Schizophrenia
rs7914558 10 104775908 G,A 0.3993 0.8939 20.439 0.08 3.36E208 ILMN_1682165 mRNA expression CRBLM 72030 NT5C2 Schizophrenia
rs102275 11 61557803 T,C 0.3279 0.9763 20.423 0.075 1.70E208 ILMN_1670134 mRNA expression CRBLM 9609 FADS1 Crohns
rs102275 11 61557803 T,C 0.3279 0.9763 20.315 0.075 2.57E205 ILMN_1670134 mRNA expression FCTX 9609 FADS1 Crohns
rs694739 11 64097233 A,G 0.4073 0.8502 20.911 0.081 2.75E229 ILMN_1772208 mRNA expression CRBLM 27286 CCDC88B Crohns
rs11175593 12 40601940 C,T 0.0189 0.9679 1.324 0.299 9.86E206 cg04575343 CpG methylation FCTX 102678 SLC2A13 Crohns
rs12817488 12 123296294 G,A 0.4249 0.8039 20.368 0.093 7.46E205 cg05384917 CpG methylation CRBLM 95341 GPR109B Parkinson
rs2942168 17 43714850 G,A 0.2538 0.9091 0.522 0.104 5.73E207 cg19832721 CpG methylation CRBLM 534966 KIAA1267 Parkinson
rs2942168 17 43714850 G,A 0.247 0.3054 20.87 0.149 5.30E209 ILMN_1709549 mRNA expression CRBLM 201405 PLEKHM1 Parkinson
rs2942168 17 43714850 G,A 0.247 0.3054 22.287 0.164 3.66E244 ILMN_2393693 mRNA expression CRBLM 130367 PLEKHM1 Parkinson
rs393152 17 43719143 A,G 0.2551 0.997 0.497 0.099 5.76E207 cg19832721 CpG methylation CRBLM 530673 KIAA1267 Parkinson
rs393152 17 43719143 A,G 0.2483 0.335 20.829 0.142 5.25E209 ILMN_1709549 mRNA expression CRBLM 205698 PLEKHM1 Parkinson
rs393152 17 43719143 A,G 0.2483 0.335 22.18 0.156 3.41E244 ILMN_2393693 mRNA expression CRBLM 134660 PLEKHM1 Parkinson
rs8070723 17 44081064 A,G 0.2547 1 0.496 0.099 5.77E207 cg19832721 CpG methylation CRBLM 168752 KIAA1267 Parkinson
rs8070723 17 44081064 A,G 0.2592 0.946 20.509 0.083 8.29E210 ILMN_1709549 mRNA expression CRBLM 567619 PLEKHM1 Parkinson
rs8070723 17 44081064 A,G 0.2592 0.946 21.265 0.091 1.07E243 ILMN_2393693 mRNA expression CRBLM 496581 PLEKHM1 Parkinson
rs199533 17 44828931 G,A 0.2386 0.8935 0.487 0.108 5.91E206 cg19832721 CpG methylation CRBLM 579115 KIAA1267 Parkinson
rs199533 17 44828931 G,A 0.2449 0.7188 20.4 0.099 5.37E205 ILMN_1698680 mRNA expression FCTX 234735 ARL17A Parkinson
rs281379 19 49214274 A,G 0.4943 0.9789 0.484 0.086 1.71E208 cg13881341 CpG methylation CRBLM 44941 FUT1 Crohns
rs281379 19 49214274 A,G 0.4943 0.9789 0.389 0.086 5.73E206 cg16155702 CpG methylation CRBLM 45936 FGF21 Crohns
rs4809330 20 62349586 G,A 0.3435 1 20.388 0.077 4.23E207 ILMN_1794643 mRNA expression CRBLM 17792 ZGPAT Crohns
rs181359 22 21928641 G,A 0.2118 0.8549 20.698 0.111 3.49E210 cg22262140 CpG methylation CRBLM 58335 FLJ36046 Crohns
rs181359 22 21928641 G,A 0.2118 0.8549 20.481 0.111 1.51E205 cg22262140 CpG methylation FCTX 58335 FLJ36046 Crohns
The table shows only significantly associated SNP-probe pairs after Bonferroni correction for multiple testing. Abbreviations include CRBLM for cerebellum, FCTX for frontal cortex and bp for base pair.
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associations (OR 1.05, a , 0.05). On the other hand, this
method cannot definitively show a true negative effect for the
other 16 intermediate risk factors investigated in this manuscript
(particularly those with robust epidemiological associations such
as smoking and caffeine intake) as the genetic contributions of
known associated SNPs may be so small, and then further diluted
in their biological relationship to PD risk, that these effects may
be of virtually undetectable magnitude at this current period in
genetic analyses.
MATERIALS AND METHODS
Data mining of PD-related traits from GWAS
The entire NHGRI GWAS catalog was downloaded on August
15, 2012. Phenotypes for each GWAS were indexed describing
the diseases and quantitative traits associated with these studies.
Based on a recently published systematic review of PD-related
factors and consultation, we assembled a list of possible comor-
bidities of interest from the GWAS catalog using the disease/trait
index (Supplementary Material, Table S1). From these indexed
disease/trait descriptions, we extracted all keywords described
in Supplementary Material, Table S1 by text mining to identify
studies of relevant phenotypes for this analysis.
To extract relevant SNPs from only high-quality studies, a
series of filters were used for SNP inclusion in the profiles
based on data from the GWAS catalog. Minimum sample sizes
for included GWAS SNPs had to be at least 1000 cases and
1000 controls for binary phenotypes in both discovery and repli-
cation analyses, and at least 1000 samples for continuous pheno-
types. In addition, since all PD GWAS samples were of European
ancestry, these sample size filters were based on European ances-
try participants within the reported GWAS only. These SNPs
must also have achieved a discovery P-value of ≤5E28 as
reported in the GWAS catalog. The contributing GWAS study
must also have made data available regarding allelic direction
of effect for the most significant SNP per locus.
Once all high-quality studies and their reported SNPs were
extracted, additional quality control was necessary prior to con-
structing phenotype-specific risk scores. For all GWAS SNPs
associated with a specific phenotype of interest, duplicate
SNPs were excluded, and SNPs within 250 kb of another SNP
associated with the same phenotype were excluded if the r2
between the two SNPs was .0.5. For SNPs in linkage disequi-
librium related to the same phenotype, the more significant
SNP based on discovery phaseP-value was kept for construction
of the risk profile scores. r2 estimates of linkage disequilibrium
were based on European ancestry samples from the most recent
1000 Genomes Project data freeze (Phase 1 alpha, version 3
available from (1)). In addition, all SNPs had to be successfully
imputed in the IPDGC cohorts participating in this analysis, see
below for details.
IPDG datasets
Genotyping data from five IPDGC cohorts with genome-wide
genotyping were extracted for use in this study. These cohorts
have been described in Table 1, and in greater detail in previous
publications (49,70). In brief, standard genome-wide association
quality control was used including inclusion criteria such as:
minimum 95% call rate per sample, Hardy–Weinberg equilib-
rium P-values .1E26, minor allele frequency .1%, missing-
ness per SNP ,5%. Additional quality control parameters for
GWAS samples included European ancestry consistent with
HapMap3 samples based on multidimensional scaling, X
chromosome heterogeneity reflecting self-reported gender per
sample, and the exclusion of cryptically related samples at the
first cousin level or closer relation. In addition, SNPs were
removed for palindromic alleles (A/T or G/C combinations), dif-
ferential missingness between cases and controls at P-value of
,1E24 and differential missingness by haplotype P-value of
,1E24. All quality control of raw genotype data was conducted
using PLINK and R (6, R Development Core Team, R: A Lan-
guage and Environment for Statistical Computing, R Foundation
for Statistical Computing, Vienna, Austria, URL http://www.
R-project.org, 2006).
After quality control, all IPDGC datasets were imputed using
the minimac implementation of the Markov Chain based haplo-
typer with reference haplotypes from the European ancestry
samples available in the August 2010 release from the 1000
Genomes project (82). After imputation, imputed dosages
were filtered based on minimum imputation quality of 0.30
(RSQR metric from MACH) and a minor allele frequency of
1% for each cohort.
Risk profile construction
For each of the 18 phenotypes of interest with high-quality SNPs
available, risk profiles were constructed. This was accomplished
by summing all imputed allele dosages from extracted SNPs for
each phenotype per cohort. The allelic dosages were quantified
as 0–2 dosages for each SNP relating to the specific allele that
was associated in previous reports with either a risk increase
for a disease phenotype or an increase in the level of a continuous
phenotype. All risk profiles were relatively normally distributed
and were then Z transformed so that effect estimates would be
easily comparable. Z transformation was undertaken using the
standard formula where individual profile scores were sub-
tracted by the mean of the population for that score and then
divided by their standard deviation.
Analyses of risk profiles
For each of the 18 profiles calculated within each of the contrib-
uting cohorts, logistic regression was used to generate summary
statistics, using the profile scores as the independent variable and
adjusting for age (at onset in cases and exam in controls), sex and
principal components 1 and 2 derived from genotyped SNPs.
The use of principal components based on an LD pruned SNP
set in each cohort as a covariate allows for population substruc-
ture to be accounted for in the regression models. Summary
statistics for each cohort were meta-analyzed to generate aggre-
gate effect estimates for all profiles using random effects
meta-analyses. For PD, schizophrenia and Crohn’s disease
related SNPs, single SNP analyses were also performed using
identical statistical methods as for the risk profile-based analyses
to facilitate an in-depth examination of the individual SNPs com-
prising these three scores.
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Expression and methylation quantitative trait analyses
Data for this aspect of analyses were made possible through col-
laborative efforts of the North American and United Kingdom
Brain Expression Consortia (83–85). Frozen frontal cortex
and cerebellar samples were obtained from .399 self-reported
European ancestry samples without determinable neuropathol-
gical evidence of disease. Genomic DNA was extracted with
phenol–chloroform. Bisulfite converted DNA and assayed at
.27 000 sites on the Illumina Infinium HumanMethylation27
BeadChips. MRNA expression levels were assayed using Illu-
mina HumanHT-12 v3 Expression Beadchips. In brief, individ-
ual probes were excluded from analyses if the P-value for
detection was .0.01 or there was ,95% completeness of data
per probe, and samples were excluded if ,95% of probes
were detected. Probes were also removed if an analyzed SNP
was within the probe or the probe mapped ambiguously to mul-
tiple locations in the genome. Expression data were cubic spline
normalized and log 2-transformed prior to analyses.
Each tissue sample was genotyped using the Illumina Human-
Hap550 v3, Human610-Quad v1 or Human660W-Quad v1 Infi-
nium Beadchips, shared SNPs were extracted prior to QC and
imputation. Standard GWAS quality control was undertaken
with inclusion criteria such as: minimum call rate 95% for both
participants and SNPs, minor allele frequency (MAF). 0.01,
HWE. 1E27, no first-degree relatives in the sample collection
(identity by descent score ,0.125 in PLINK) and European
ancestry confirmed by multidimensional scaling analyses.
Data were imputed using MiniMac (http://genome.sph.umich.
edu/wiki/Minimac) to the most recent data freeze of 1000 Geno-
mes haplotypes (http://www.sph.umich.edu/csg/abecasis/MaCH/
download/1000G.2012-03-14.html) using default settings. All
imputed SNPs were filtered for a minimum imputation quality of
0.30. After quality control, data were available for .10 million
SNPs, with expression data on 399 samples (9814 probes from
the frontal cortex and 9587 probes in cerebellum) and methylation
data on 292 samples (27465 CpG sites in the frontal cortex tissue
samples and 27419 CpG sites in the cerebellum).
Linear regression models were utilized to estimate associations
between allele dosages of per SNP and gene expression or methy-
lation levels adjusted for covariates of gender, age at death, the first
two component vectors from multidimensional scaling, post-
mortem interval, brain bank and batch in which preparation or
hybridization were performed, using MACH2QTLv1.11 (http://
www.sph.umich.edu/csg/abecasis/MaCH/download/). Analyses
were carried out separately for each brain region and each array
type. Only probes within +1 mb of SNPs of interest in this
study were analyzed to test only cis associations. From these ana-
lysis results, data were mined for SNPs comprising the Crohn’s
disease, PD and schizophrenia risk profiles. Multiple test correc-
tion was based on simple Bonferroni correction stratified by
brain region and assay type.
Systematic review of epidemiological data
Validation of the findings of associations of a genetic profile PD
with genetic risk profiles for other conditions or behaviors was
sought by comparison with published data from epidemiological
studies on their clinical associations. A recent systematic review
and meta-analysis reported the combined results from case–
control and cohort studies on association of PD with preceding
smoking, coffee drinking, hypertension, diabetes, raised serum
urate and obesity. For full details of the search strategy, inclusion
and exclusion criteria and analysis of data see Noyce et al. (1). A
separate meta-analysis on association of PD with preceding as
well as existing diagnosis of melanoma (86) included publications
until June 2010 and no further relevant papers were published
from October 2010 to March 2011; and a another meta-analysis
on association of existing PD with iron levels included publica-
tions until 2011 (87). For the other factors that had not fulfilled in-
clusion criteria in these meta-analyses, individual publications
that reported case–control or cohort studies in the general PD
population up to March 31, 2011 were identified. From these pub-
lications, the number of studies, number of cases and controls, OR
with 95% confidence intervals, standard errors, I2 statistic, and
P-values for risk and heterogeneity (in the meta-analyses) were
extracted or calculated.
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